U.S. markets open in 58 minutes
  • S&P Futures

    4,220.25
    +6.50 (+0.15%)
     
  • Dow Futures

    33,795.00
    +34.00 (+0.10%)
     
  • Nasdaq Futures

    14,165.00
    +35.00 (+0.25%)
     
  • Russell 2000 Futures

    2,279.80
    -1.10 (-0.05%)
     
  • Crude Oil

    73.02
    -0.64 (-0.87%)
     
  • Gold

    1,779.70
    -3.20 (-0.18%)
     
  • Silver

    25.94
    -0.08 (-0.31%)
     
  • EUR/USD

    1.1895
    -0.0030 (-0.25%)
     
  • 10-Yr Bond

    1.4840
    0.0000 (0.00%)
     
  • Vix

    17.36
    -3.34 (-16.14%)
     
  • GBP/USD

    1.3897
    -0.0036 (-0.26%)
     
  • USD/JPY

    110.5500
    +0.2520 (+0.23%)
     
  • BTC-USD

    29,876.91
    -2,922.40 (-8.91%)
     
  • CMC Crypto 200

    713.60
    -136.74 (-16.08%)
     
  • FTSE 100

    7,088.31
    +26.02 (+0.37%)
     
  • Nikkei 225

    28,884.13
    +873.20 (+3.12%)
     

AstraZeneca, Daiichi Sankyo Partnered ADC Shows Promise In Hard-To-Treat Breast Cancer

  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • AstraZeneca Plc (NASDAQ: AZN) and Daiichi Sankyo (OCTMKTS: DSNKY) have announced an update from their second antibody-drug conjugate (ADC) program that is showing promise in hard-to-treat breast cancer.

  • The ADC, datopotamab deruxtecan, posted a 43% response rate and five confirmed complete or partial responses among 21 patients with triple-negative breast cancer, according to cohort data from the TROPION-PanTumor01 Phase 1 study presented at the virtual ESMO Breast annual meeting 2021.

  • The majority of those patients were treated with 6-mg doses of the drug, while two received an 8-mg high dose.

  • Five confirmed complete (CR) or partial responses (PR) were also seen, with four additional CR/PRs awaiting confirmation at the time of data cutoff on January 8. A disease control rate of 95% was also observed.

  • Meanwhile, the TNBC cohort reported zero cases of interstitial lung disease.

  • The drug combines an antibody targeting TROP2 that's conjugated using a stable linker with a potent topoisomerase I inhibitor payload. It has a lower drug-to-antibody ratio that Daiichi suggests should both boost cell-killing activity and limit side effects.

  • Price Action: AZN shares are trading 0.8% higher at $54.25 during the premarket session on the last check Monday, while DSNKY shares closed $25.86 on Friday

See more from Benzinga

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.